Sienna Biopharmaceuticals cuts expenses, net losses
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Read More →FDA approves biosimilar competitor to Amgen’s Enbrel
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Read More →Sientra stock falls after company warned by FDA over study
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Read More →Calavo Growers reports lower first quarter net income
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Read More →Federal shutdown took a toll in the Tri-Counties
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Read More →Our view: Government shutdown should end immediately
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Read More →FDA committee OKs Amgen’s Evenity
A U.S. Food and Drug Administration advisory committee voted in favor of a new approval for Amgen’s osteoporosis treatment Evenity for use by postmenopausal women. The Bone, Reproductive and Urologic Drugs Advisory Committee voted to approve the expanded use of the treatment following the release of new safety and efficacy data and emphasized the need Read More →
Read More →
Sponsored content:
2015-2016 Giving Guide
